Hawkins just dropped its Q2 2027 scorecard and the stock exploded higher, jumping 13.6% in a single session to about $153.85. That is an emotional move for a chemicals stock, and it landed on a quarter where basic earnings per share came in at about $1.34 on revenue of roughly $313.8 million.
The real flashpoint is valuation. This business already trades on a trailing P/E of 37.3x, well above both the US chemicals industry and peer averages, so every quarterly print becomes a referendum on whether that premium is still deserved.
Like the earnings pop in Hawkins but uneasy with a 37.3x P/E on a chemicals stock? Benchmark that premium against a curated screener of list of solid balance sheet and fundamentals stocks (24 results).
Q2 2027 Earnings Summary
- Revenue (Q2 2027 vs Q2 2026): US$313.8 million vs. US$280.4 million (up about 11.9%)
- Net Income, Excluding Extra Items (Q2 2027 vs Q2 2026): US$27.8 million vs. US$22.6 million (up about 22.9%)
- Basic EPS (Q2 2027 vs Q2 2026): US$1.34 vs. US$1.09 (up about 23.1%)
- Trailing 12 Month Net Profit Margin (Q2 2027 vs Q2 2026): 7.5% vs. 8.0% (margin compressed by 0.5 percentage points)
Prefer clear charts instead of staring at another wall of Hawkins financials and raw numbers? See the full visual picture of the business, including its valuation profile, in the interactive company report for Hawkins.
Hawkins results backing the steady-operator story
For anyone leaning toward the Hawkins steady infrastructure narrative, these numbers broadly cooperate. Revenue and net income both moved higher at a double digit clip, while EPS advanced even faster, which fits a picture of a chemicals supplier that is doing more than just holding the line. Margin compression to 7.5% from 8.0% softens that story a bit, yet debt reduction, consistent dividends and early contributions from recent water treatment acquisitions all lean in the direction of a resilient, essentials focused business model.
Where the Hawkins bear worries still bite
There is still ammunition for a more cautious stance. Profitability compressed year on year, which ties directly into long running concerns about input costs and pricing power in chemicals. The heavy focus on acquisitions in water treatment also cuts both ways. It supports growth in a higher margin area but raises questions about integration risk and how much of current revenue traction comes from bought rather than internally generated volume. For investors worried about cyclicality and regulation, the quarter reduces some anxiety but does not clear the deck.
An elevated P/E, softer recent earnings growth and margin pressure already raise questions about how much strain Hawkins can absorb if conditions tighten more abruptly. Check the full solvency, liquidity and cash coverage picture in the financial health analysis of Hawkins stock
Hunt For Pre-Priced Strength
Hawkins shows how quickly sentiment can shift when a premium story faces renewed scrutiny. The real opportunity is in stocks that could be undervalued before any repricing appears in trading data.
- Company 1 - 23% below our estimate - uses surgical robotics and higher acuity procedures to broaden procedure coverage and deepen equipment demand.
- Company 2 - 27% below our estimate - supplies custom chips and software that move, connect and secure data as enterprises scale digital infrastructure.
- Company 3 - 42% below our estimate - enables large merchants to manage complex cross border pay-ins and pay-outs through one localised payments platform.
Three companies from the same screener. Open all 29 potentially undervalued companies →
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com